PMID- 35687867
OWN - NLM
STAT- MEDLINE
DCOM- 20220728
LR  - 20221201
IS  - 1747-6356 (Electronic)
IS  - 1747-6348 (Linking)
VI  - 16
IP  - 6
DP  - 2022 Jun
TI  - Bronchiectasis in patients with antineutrophil cytoplasmic antibody-associated 
      vasculitis: a case control study on clinical features and prognosis.
PG  - 697-705
LID - 10.1080/17476348.2022.2088512 [doi]
AB  - BACKGROUND: Bronchiectasis was reported in 2%-40% of patients with antineutrophil 
      cytoplasmic antibody-associated vasculitis (AAV), but there were no studies on 
      the prevalence, risk factors and impact of AAV-associated bronchiectasis in 
      Chinese patients. RESEARCH DESIGN AND METHODS: AAV patients were retrospectively 
      enrolled. The clinical, laboratory and imaging features and the prognosis were 
      analyzed and compared between those with and without bronchiectasis. RESULTS: 
      Bronchiectasis was present in 48/212 (22.6%) of our AAV patients, among whom 41 
      were confirmed in 210 patients (19.5%) who received chest HRCT at the initial 
      diagnosis of AAV. There were more women and fewer smokers in those with 
      bronchiectasis as compared to those without. Cases with positive anti-MPO were 
      more likely to have bronchiectasis (26.2%), and those with bronchiectasis were 
      more likely to be anti-MPO positive (93.8%). Patients who had a diagnosis of 
      bronchiectasis before AAV were more likely to have nervous system involvement, 
      while patients without bronchiectasis had higher 24h proteinuria. The presence of 
      bronchiectasis showed no significant effect on the 1, 3, 5-year survival. 
      CONCLUSIONS: Nearly 20% of patients showed bronchiectasis on chest HRCT at the 
      initial diagnosis of AAV, and positivity of anti-MPO was associated with 
      bronchiectasis in a Chinese cohort of AAV patients.
FAU - Ren, Jiaqi
AU  - Ren J
AD  - Department of Respiratory and Critical Care Medicine, Peking University Third 
      Hospital, Beijing, Haidian, China.
FAU - Ding, Yanling
AU  - Ding Y
AD  - Department of Respiratory and Critical Care Medicine, Peking University Third 
      Hospital, Beijing, Haidian, China.
FAU - Zhao, Jinxia
AU  - Zhao J
AD  - Department of Rheumatology and Immunology, Peking University Third Hospital, 
      Beijing, Haidian, China.
FAU - Sun, Yongchang
AU  - Sun Y
AD  - Department of Respiratory and Critical Care Medicine, Peking University Third 
      Hospital, Beijing, Haidian, China.
LA  - eng
PT  - Journal Article
DEP - 20220616
PL  - England
TA  - Expert Rev Respir Med
JT  - Expert review of respiratory medicine
JID - 101278196
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - EC 1.11.1.7 (Peroxidase)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/complications/epidemiology
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - *Bronchiectasis/epidemiology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Peroxidase
MH  - Prognosis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Antineutrophil cytoplasmic antibody-associated vasculitis
OT  - bronchiectasis
OT  - clinical research
OT  - prognosis
OT  - retrospective study
EDAT- 2022/06/11 06:00
MHDA- 2022/07/29 06:00
CRDT- 2022/06/10 17:02
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/07/29 06:00 [medline]
PHST- 2022/06/10 17:02 [entrez]
AID - 10.1080/17476348.2022.2088512 [doi]
PST - ppublish
SO  - Expert Rev Respir Med. 2022 Jun;16(6):697-705. doi: 
      10.1080/17476348.2022.2088512. Epub 2022 Jun 16.